Annual CFO
-$127.16 M
-$127.48 M-39590.06%
December 31, 2023
Summary
- As of February 25, 2025, RPTX annual cash flow from operations is -$127.16 million, with the most recent change of -$127.48 million (-39590.06%) on December 31, 2023.
- During the last 3 years, RPTX annual CFO has fallen by -$121.07 million (-1990.04%).
- RPTX annual CFO is now -39590.06% below its all-time high of $322.00 thousand, reached on December 31, 2022.
Performance
RPTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$30.54 M
-$25.00 K-0.08%
September 30, 2024
Summary
- As of February 25, 2025, RPTX quarterly cash flow from operations is -$30.54 million, with the most recent change of -$25.00 thousand (-0.08%) on September 30, 2024.
- Over the past year, RPTX quarterly CFO has increased by +$2.33 million (+7.09%).
- RPTX quarterly CFO is now -134.64% below its all-time high of $88.16 million, reached on September 30, 2022.
Performance
RPTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$77.28 M
+$2.33 M+2.93%
September 30, 2024
Summary
- As of February 25, 2025, RPTX TTM cash flow from operations is -$77.28 million, with the most recent change of +$2.33 million (+2.93%) on September 30, 2024.
- Over the past year, RPTX TTM CFO has increased by +$51.36 million (+39.93%).
- RPTX TTM CFO is now -756.56% below its all-time high of $11.77 million, reached on June 30, 2020.
Performance
RPTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
RPTX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -10000.0% | +7.1% | +39.9% |
| 3 y3 years | -1990.0% | +6.8% | +0.9% |
| 5 y5 years | -907.8% | -421.9% | -319.3% |
RPTX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | <-9999.0% | at low | -134.6% | +11.1% | -938.0% | +39.9% |
| 5 y | 5-year | <-9999.0% | at low | -134.6% | +11.1% | -756.6% | +39.9% |
| alltime | all time | <-9999.0% | at low | -134.6% | +11.1% | -756.6% | +39.9% |
Repare Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$30.54 M(+0.1%) | -$77.28 M(-2.9%) |
| Jun 2024 | - | -$30.51 M(-355.7%) | -$79.61 M(-4.6%) |
| Mar 2024 | - | $11.93 M(-142.4%) | -$83.44 M(-34.4%) |
| Dec 2023 | -$127.16 M(<-9900.0%) | -$28.16 M(-14.3%) | -$127.16 M(-1.2%) |
| Sep 2023 | - | -$32.87 M(-4.3%) | -$128.64 M(+1590.2%) |
| Jun 2023 | - | -$34.35 M(+8.1%) | -$7.61 M(+422.0%) |
| Mar 2023 | - | -$31.79 M(+7.3%) | -$1.46 M(-552.8%) |
| Dec 2022 | $322.00 K(-100.4%) | -$29.64 M(-133.6%) | $322.00 K(-96.5%) |
| Sep 2022 | - | $88.16 M(-412.7%) | $9.22 M(-108.3%) |
| Jun 2022 | - | -$28.19 M(-6.0%) | -$111.71 M(+10.0%) |
| Mar 2022 | - | -$30.01 M(+44.7%) | -$101.58 M(+18.4%) |
| Dec 2021 | -$85.80 M | -$20.74 M(-36.7%) | -$85.80 M(+10.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$32.77 M(+81.5%) | -$78.00 M(+19.4%) |
| Jun 2021 | - | -$18.06 M(+26.9%) | -$65.34 M(+516.7%) |
| Mar 2021 | - | -$14.23 M(+9.9%) | -$10.59 M(+74.1%) |
| Dec 2020 | -$6.08 M(-67.0%) | -$12.95 M(-35.6%) | -$6.08 M(+145.0%) |
| Sep 2020 | - | -$20.10 M(-154.8%) | -$2.48 M(-121.1%) |
| Jun 2020 | - | $36.68 M(-477.5%) | $11.77 M(-138.0%) |
| Mar 2020 | - | -$9.72 M(+4.0%) | -$31.00 M(+68.2%) |
| Dec 2019 | -$18.43 M(+46.1%) | -$9.35 M(+59.7%) | -$18.43 M(+102.9%) |
| Sep 2019 | - | -$5.85 M(-3.8%) | -$9.08 M(+181.0%) |
| Jun 2019 | - | -$6.08 M(-313.4%) | -$3.23 M(-213.4%) |
| Mar 2019 | - | $2.85 M | $2.85 M |
| Dec 2018 | -$12.62 M(+110.1%) | - | - |
| Dec 2017 | -$6.01 M | - | - |
FAQ
- What is Repare Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Repare Therapeutics?
- What is Repare Therapeutics annual CFO year-on-year change?
- What is Repare Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Repare Therapeutics?
- What is Repare Therapeutics quarterly CFO year-on-year change?
- What is Repare Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Repare Therapeutics?
- What is Repare Therapeutics TTM CFO year-on-year change?
What is Repare Therapeutics annual cash flow from operations?
The current annual CFO of RPTX is -$127.16 M
What is the all time high annual CFO for Repare Therapeutics?
Repare Therapeutics all-time high annual cash flow from operations is $322.00 K
What is Repare Therapeutics annual CFO year-on-year change?
Over the past year, RPTX annual cash flow from operations has changed by -$127.48 M (-39590.06%)
What is Repare Therapeutics quarterly cash flow from operations?
The current quarterly CFO of RPTX is -$30.54 M
What is the all time high quarterly CFO for Repare Therapeutics?
Repare Therapeutics all-time high quarterly cash flow from operations is $88.16 M
What is Repare Therapeutics quarterly CFO year-on-year change?
Over the past year, RPTX quarterly cash flow from operations has changed by +$2.33 M (+7.09%)
What is Repare Therapeutics TTM cash flow from operations?
The current TTM CFO of RPTX is -$77.28 M
What is the all time high TTM CFO for Repare Therapeutics?
Repare Therapeutics all-time high TTM cash flow from operations is $11.77 M
What is Repare Therapeutics TTM CFO year-on-year change?
Over the past year, RPTX TTM cash flow from operations has changed by +$51.36 M (+39.93%)